1	Title Page
2	Manuscript Title: Efficacy of Anakinra in the Management of Patients with
3	COVID-19 Infection: A Randomized Clinical Trial
4	Running Title: Anakinra in COVID-19 Infection
5	
6	Authors Affiliations
7	Eman Zeyad I. Elmekaty*, PharmD
8	Communicable Diseases Center, Hamad Medical Corporation
9	PO BOX 3050, Doha, Qatar
10	Email: <u>eelmekaty@hamad.qa</u>
11	Aya Maklad, PharmD
12	College of Pharmacy, QU Health, Qatar University,
13	PO BOX 2713, Doha, Qatar
14	Email: am1402005@student.qu.edu.qa
15	Rawan Abouelhassan, PharmD
16	College of Pharmacy, QU Health, Qatar University,
17	PO BOX 2713, Doha, Qatar
18	Email: ra1406526@student.qu.edu.qa
19	Waqar Munir, CABM
20	Communicable Diseases Center, Hamad Medical Corporation
21	PO BOX 3050, Doha, Qatar
22	Email: <u>WMunir@hamad.qa</u>
23	Mohamed Izham Mohamed Ibrahim, PhD
24 25	Clinical Pharmacy & Practice Department, College of Pharmacy, QU Health, Qatar University
26	PO Box: 2713, Doha, Qatar.
27	Email: <u>mohamedizham@qu.edu.qa</u> Page 1 of 22

- 28 Arun Nair, MBBS MD
- 29 Communicable Diseases Center, Hamad Medical Corporation
- 30 PO BOX 3050, Doha, Qatar
- 31 Email: <u>ANair9@hamad.qa</u>
- 32 **Rim Alibrahim,** PharmD
- 33 Communicable Diseases Center, Hamad Medical Corporation
- 34 PO BOX 3050, Doha, Qatar
- 35 Email: <u>RAlibrahim@hamad.qa</u>
- 36 **Fatima Iqbal,** PharmD
- 37 Communicable Diseases Center, Hamad Medical Corporation
- 38 PO BOX 3050, Doha, Qatar
- 39 Email: Flqbal1@hamad.qa
- 40 Ahmad Al Bishawi, MD
- 41 Communicable Diseases Center, Hamad Medical Corporation
- 42 PO BOX 3050, Doha, Qatar
- 43 Email: <u>AAlBishawi@hamad.qa</u>

44 Alaaeldin Abdelmajid, MD

- 45 Communicable Diseases Center, Hamad Medical Corporation
- 46 PO BOX 3050, Doha, Qatar
- 47 Email: <u>AAbdelmajid@hamad.qa</u>

48 Mohamed Aboukamar, CABM

- 49 Communicable Diseases Center, Hamad Medical Corporation
- 50 PO BOX 3050, Doha, Qatar
- 51 Email: <u>Mkamar@hamad.qa</u>

52 Mohammed Abu Khattab, CABM

- 53 Communicable Diseases Center, Hamad Medical Corporation
- 54 PO BOX 3050, Doha, Qatar

- 55 Email: <u>MABUKHATTAB@hamad.qa</u>
- 56 Hussam Al Soub, CABM

57	Communicable Diseases Center, Hamad Medical Corporation
58	PO BOX 3050, Doha, Qatar
59	Email: <u>HALSOUB@hamad.qa</u>
60	Muna Al Maslamani, MBBS MSc-HCM
61	Medical Director of Communicable Diseases Center, Hamad Medical Corporation
62	PO BOX 3050, Doha, Qatar
63	Email: MALMASLAMANI@hamad.qa
64	
65	
66	
67	
68	* Corresponding Author
69	Dr. Eman Zeyad Ibrahim Elmekaty, BSc (Pharm), PharmD, RPh, SIDP/ASCP, BCIDP
70	Clinical Pharmacist - Infectious Disease
71	Communicable Disease Center – HMC
72	Tel: (+974) 40254259
73	P.O. Box 3050 Doha, Qatar
74	Eelmekaty@hamad.qa
75	
76	

77

Efficacy of Anakinra in the Management of Patients with COVID-19 Infection: A Randomized Clinical Trial

80 Abstract

Background: The global pandemic of COVID-19 infections continues to grow worldwide, with rising
number of deaths day by day. The hyperinflammation state contributes to the multiorgan failure
associated with COVID-19 infections. This study aims to explore the efficacy and safety of anakinra in
COVID-19 patients with both respiratory distress and cytokine release syndromes.

85

Methods: This was an open-label, multicenter, randomized clinical trial. Patients were randomized in 1:1
 ratio to receive standard of care (SOC) alone, or anakinra plus SOC. Adults with confirmed COVID-19
 infection with evidence of both respiratory distress and cytokine release syndrome were included. The
 primary outcome was treatment success at day 14, defined as WHO clinical progression score of ≤3. The
 primary analysis was based on intention-to-treat population, with p-value of <0.05.

91

92 Results: A total of 80 patients were enrolled in the study. The mean age was 49.9 years (SD=11.7), with 93 82.5% (n=66) male patients. The primary outcome was not statistically different (87.5% (n=35) in 94 anakinra group vs. 92.5% (n=37) in SOC group, p=0.712). The majority of reported adverse events were 95 mild in severity and not related to the study treatment. Increased aspartate aminotransferase was the 96 only significant adverse event (35% (n=14) in anakinra group vs. 15% (n=6) in SOC group, p=0.039); yet, 97 was not associated with treatment discontinuation.

98

99 Conclusion: In patients with severe COVID-19 infection, the addition of anakinra to SOC treatment was 100 not associated with significant improvement in the WHO clinical progression scale. Further studies 101 investigating patients' subgroups that might benefit from anakinra are warranted. The trial was registered 102 at ClinicalTrials.gov (NCT04643678).

103

104 Keywords:

105 Anakinra, COVID-19, Interlukin-1 inhibitor, SARS-COV-2, Cytokine release syndrome, Severe pneumonia. Page **4** of **22**

106 Introduction:

107 Since its declaration by the World Health Organization (WHO) in March 2020 as a global pandemic, the 108 severe acute respiratory syndrome coronavirus (SARS-CoV-2), also known as COVID-19, continues to 109 spread worldwide with increasing daily fatalities ^[1]. Subsequently, as of September 2021, the total number 110 of confirmed COVID-19 infections has exceeded 200,000,000 cases, with a total of 4,500,000 recorded 111 deaths globally ^[2]. Although the majority of confirmed infections present with mild to moderate clinical 112 presentations ranging from the absence of symptoms to the loss of taste or smell, headache, fatigue or 113 fever, COVID-19 may still result in consequent severe sequelae, including acute respiratory distress 114 syndrome (ARDS) and organ dysfunction syndrome along with an estimated mortality rate of 3.4% ^[3,4].

115 The infection acts as an essential source for activating macrophages, resulting in the release of pro-116 inflammatory cytokines and chemokine macrophages primarily in the lungs, followed by subsequent 117 systemic release. This process is thought to play a major role in the pathophysiology of organ dysfunction 118 syndrome ^[5]. Furthermore, cytokine storm syndrome, a state of hyper-inflammation that contributes to 119 multiorgan failure, has proven to share considerable biochemical overlap with the hyper-inflammation 120 observed in patients with confirmed COVID-19 infections. Accordingly, recent evidence hypothesized that 121 screening COVID-19 patients for hyper-inflammation and consequently providing management with 122 immunosuppressive medications could improve mortality ^[6,7].

Anakinra, a recombinant non-glycosylated form of the human interleukin (IL)-1 receptor antagonist, has demonstrated significant survival benefits in patients with macrophage activation syndrome (MAS) as compared to placebo, with a 28-day mortality rate of 35% and 65%, respectively (p = 0.0006) in a subgroup analysis of patients with hyper-inflammation as a result of severe sepsis ^[8]. Furthermore, numerous studies revealed that the administration of anakinra was associated with an acceptable safety profile where recent literature reported mild elevations in liver aminotransferases as the most common adverse effect; however, such elevations were not clinically significant ^[9,10].

Meanwhile, ongoing trials are being conducted to investigate further the efficacy and safety profile of anakinra in COVID-19 patients exhibiting features of cytokine storm during their illness. Thus far, a variety of published data has shown promising results. However, such findings require extensive assessments in a well-conducted randomized controlled trial to confirm the reported outcomes ^[11,12]. Currently, there are no approved treatments directly targeted towards ceasing the cytokine storm and its consequences. Thus, this randomized clinical, open-label trial aims to explore the efficacy and safety of anakinra in addition to

136 standard of care (SOC) compared to SOC alone in patients with confirmed COVID-19 infection with

- 137 respiratory distress and evidence of cytokine release syndrome.
- 138
- 139 Methods:

140 Study design and setting

This study was a prospective randomized clinical, open-labeled, parallel assignments, multicenter trial. Patients were recruited from three clinical sites in Qatar: Communicable Disease Center (CDC), Hazm Mebaireek General Hospital (HMGH), and The Cuban Hospital (TCH) between 30 October 2020 till 30 April 2021. Eligible patients were randomized to receive either anakinra + SOC or SOC alone. The trial protocol and the statistical analysis plan is available online. The trial was approved by the Institutional Review Board at Hamad Medical Corporation (HMC) Medical Research Center (MRC-01-20-1095) and was registered at ClinicalTrials.gov (NCT04643678).

148 *Participants*

149 Hospitalized adults (age \geq 18yrs) were eligible for inclusion in the trial if they met the following eligibility 150 criteria: confirmed COVID-19 diagnosis by positive SARS-CoV2 Polymerase Chain Reaction (PCR) test and 151 associated presence of respiratory distress [defined as: PaO2/FiO2 ≤ 300 mm Hg or respiratory Rate (RR) 152 \geq 24 breaths/min or SpO2 \leq 94% at room air], signs of cytokine release syndrome [defined as any of the 153 following at baseline: Ferritin >600 mcg/L at presentation or >300 mcg/l with doubling within 24 hours, 154 LDH >250 IU/L, D-dimers > 1 mg/L, CRP > 70mg/L and rising since last 24h with the absence of bacterial 155 infection, Interleukin-6 level > 10 x UNL (reference range $\leq 7 \text{ pg/ml}$), radiological evidence of pneumonia 156 based on chest X-ray and/or computed tomography (CT) scan findings, and a signed informed consent 157 provided by the patient, or by the patient's legal representative. The exclusion criteria included known 158 serious allergic reactions including anaphylaxis to the study medication or any component of the product, 159 active infectious diseases such as active bacterial infections (defined as the isolation of bacteria from a 160 sterile body site or other body sites and is causing clinical symptoms and signs and therefore are treated 161 with antibiotics), invasive fungal infections, Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) 162 infection, Hepatitis C Virus (HCV) infection, active tuberculosis, patients on immunosuppressants or 163 immunomodulatory drugs or had received any in the past 30 days, neutrophil count below 500 164 cells/microliter, platelets below 50,000/microliter, pregnant or breastfeeding females. A full list of 165 eligibility criteria is provided in the supplementary materials.

166 Randomization and masking

167 All admissions with a laboratory-confirmed SARS-CoV-2 infection and on respiratory distress were 168 screened for eligibility by the research team. Eligible patients were randomly assigned using simple 169 randomization at an allocation ratio of 1:1 to receive either anakinra plus SOC therapy or SOC therapy 170 alone. A random sequence of numbers was generated by an independent biostatistician using a 171 computerized system. Only the principle investigator was responsible to allocate the participant serial 172 number and inform the research team of the treatment allocation. Each participant was assigned an 173 identification code corresponding to a study treatment group. The study was not blinded due to practical 174 reasons and the differences in the dosage regimens and administrations between the study groups.

175 Interventions and Procedures

176 Patients in the intervention group received anakinra (KINERET[®], 100mg/0.67 ml in pre-filled syringe) 100 177 mg subcutaneous (SC) injection every 12 hours for 3 days, then 100 mg SC once daily from day 4 to day 7. 178 The total duration of anakinra was 7 days with a total of 10 doses. Patients with severe renal impairment 179 (creatinine clearance <30 ml/min) had a 50% decrease in dose (dose administered every other day). 180 Patients in the intervention group received anakinra in addition to standard of care therapy except for 181 tocilizumab, due to the contraindication of administering both agents concomitantly. Patients in the 182 comparator group received SOC therapy as per the local treatment guideline as approved by the Ministry 183 of Public Health (MoPH) in Qatar at that time (see supplementary material). According to the treating 184 physician's judgment, therapy was discontinued, or doses were adjusted based on the safety concerns or 185 issues related to concomitant drug interactions. Apart from the study interventions and related laboratory 186 and diagnostic assessments, patients were treated as part of standard care, with no co-medications, 187 medical procedures, or diet restrictions. The study had pragmatic and adaptive nature, which mimics the 188 usual clinical practice in a real-world setting and allows for changes in the management of COVID-19 189 patients and SOC therapy, as approved by the MoPH in the country.

After enrollment, a detailed review of the participant's medical profile was conducted by the research team. Demographic, clinical, radiological, laboratory data were collected from each patient's profile. The WHO Clinical Progression Scale^[13] was used to assess the patient's clinical condition on a daily basis and was documented in the electronic data collection sheet. The worst score on each particular day was selected and recorded. The data collection sheet was validated independently by two investigators. The list of study procedures, timings, and follow-up is available in the supplementary materials. All adverse events (AEs) that occurred during the hospital stay and up to 28 days from randomization were reported. Participants were contacted by telephone using standardized telephone script on days 14 and 28 to ascertain information related to AEs. All AE were assessed for severity and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5⁽¹⁴⁾. A blinded assessor evaluated and validated the AE's severity, seriousness, relatedness, and attribution using appropriate scales and/or definitions as per the HMC IRB Standard Operating Procedure (SOP) guidelines.

202 Outcomes

The primary outcome was treatment success on day 14, defined as a WHO Clinical Progression score of Sa [Ambulatory mild disease: symptomatic, assistance needed]. Secondary outcomes included the duration of mechanical ventilation in ventilated patients up to 14 days, changes in the WHO Clinical Progression Score between day 1 and day 7, viral burden as measured by the change in SARS-CoV-2 PCR Cycle Threshold (CT) at day 7 and day 10-14, time to ICU admission up to 28 days, the incidence of adverse events up to 28 days, length of hospital stay up to 28 days, and all-cause mortality rate at hospital discharge or at 28 days, whichever occurred first.

210 Statistical analysis:

211 No published randomized trials evaluated the difference between the two study interventions at the time 212 of study planning to appropriately estimate the mean difference and compute the sample size calculation. 213 Therefore, a sample size of 80 patients was estimated for this RCT with parallel group design based on the 214 hypothesized effect size from published observational studies with 80% power to detect a difference in 215 the primary endpoint of 30%, with a two-sided type I error rate of 0.05 (alpha). Categorical data were 216 expressed by frequency (percentage), while continuous values were expressed as mean \pm SD or median 217 and interquartile range (IQR), as appropriate. Data were tested for their normality. Kolmogorov-Smirnov 218 test was carried to test for data normality. Continuous data were examined with the Mann–Whitney U or 219 independent t-test and categorical data with the chi-square and Fisher's Exact tests. Two-way repeated 220 measure ANOVA analyzed the changes of data over time in the two treatment groups. Factors significant 221 at univariate analysis (p<0.10) were further assessed by the multivariable binary regression analysis. All 222 statistical analyses were carried out using the statistical package SPSS, version 27 (IBM Corp. Released 223 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp). The primary analysis was 224 based on an intention-to-treat population, including all participants randomized.

225

226 Role of the funding source

- The study is funded by Medical Research Center at Hamad Medical Corporation, Qatar. The study's funder
 had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
- The corresponding author has full access to the data and the final responsibility to submit for publication.

230 Ethics Statement

231 The trial was approved by the Institutional Review Board at Hamad Medical Corporation (HMC) Medical 232 Research Center (MRC-01-20-1095) and was registered at ClinicalTrials.gov (NCT04643678). The trial was 233 conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of 234 Helsinki. An independent institutional review board and ethics committee approved the trial protocol and 235 any subsequent amendments. The safety of the participants and the evaluation of the benefit-risk balance 236 was overseen by an independent data safety monitoring committee. Written informed consent was 237 obtained from all participants or legally authorized representatives before initiating any trial-related 238 procedures. No additional administrative permissions were required to access the raw data. All data used 239 in this study were fully anonymized before their use.

240

241 Results:

242 Participants

Between 30 October 2020 and 28 February 2021, 327 patients were screened for eligibility and 80 patients were enrolled and randomized to the two study groups: 40 patients in anakinra group and 40 patients in the SOC group. One patient in the SOC group was lost to follow-up and discharged from the hospital for social reasons [Figure 1]. All patients randomized were included in the intention to treat analysis. As enrolled patients were hospitalized during the treatment course, the compliance with study medication was 100%.

- 249
- 250
- 251
- 252
- 253



264 Figure 1: Flow diagram

265 The baseline characteristics of the patients were summarized in table 1. No significant differences were

found (p>0.05) between the two treatment groups. The complete list of participants demographics,

267 clinical data, and concomitant medications is available in the supplementary materials.

Table 1: Baseline characteristics of the study population					
Characteristic	Overall	Anakinra	Standard of care	P-value	
	(n=80)	(n=40)	(n=40)		
Mean Age, year (SD)	49.9 (11.7)	49.5 (12.2)	50.3 (11.4)	0.77	
Gender, n (%)				0.556	
Male	66 (82.5)	32 (80)	34 (85)		
Female	14 (17.5)	8 (20)	6 (15)		
WHO Nationality Region, n (%)				0.074	
AFRO	1 (1.3)	1 (2.5)	0 (0)		
РАНО	1 (1.3)	0 (0)	1 (2.5)		
SEARO	34 (42.5)	13 (32.5)	21 (52.5)		
EURO	2 (2.5)	0 (0)	2 (5.0)		
EMRO	26 (32.5)	14 (35.0)	12 (30.0)		
WPRO	16 (20.0)	12 (30.0)	4 (10.0)		
Body Mass Index, median (IQR)	29.9 (27.3 - 32.9)	30.9 (7.0)	29.3 (5.2)	0.285	
Smoking Status, n (%)				1.00	

Non-Smoker	72 (90.0)	36 (90.0)	36 (90.0)	
Current Smoker	0 (0)	0	0	
Ex-Smoker	8 (10.0)	4 (10.0)	4 (10.0)	
Hospital, n (%)				0.535
CDC	18 (22.5)	11 (27.5)	7 (17.5)	
HMGH	44 (55.0)	20 (50.0)	24 (60.0)	
ТСН	18 (22.5)	9 (22.5)	9 (22.5)	
Nurse Unit, n (%)				1.00
General Ward	70 (87.5)	35 (87.5)	35 (87.5)	
Intensive Care Unit	10 (12.5)	5 (12.5)	5 (12.5)	
Has at least one comorbidity, n (%)	37 (46.3)	17 (42.5)	20 (50.0)	0.501
Myocardial Infarction	7 (8.8)	2 (5.0)	5 (12.5)	0.432
Chronic Obstructive Pulmonary	1 (1.3)	0 (0)	1 (2.5)	1
Disease				
Liver Disease	1 (1.3)	1 (2.5)	0 (0)	1
Diabetes Mellitus	35 (43.8)	17 (42.5)	18 (45.0)	0.822
Kidney Disease	1 (1.3)	0 (0)	1 (2.5)	1
Charlson Comorbidity Index (CCI), n (%)				
<2	72 (90.0)	37 (92.5)	35 (87.5)	0.712
≥2	8 (10.0)	3 (7.5)	5 (12.5)	
Symptoms at baseline, n (%)				
Cough	75 (93.8)	36 (90.0)	39 (97.5)	0.359
Fever	69 (86.3)	34 (85.0)	35 (87.5)	0.745
Shortness of Breath	59 (73.8)	29 (72.5)	30 (75.0)	0.799
Sore Throat	12 (15.0)	4 (10.0)	8 (20.0)	0.21
Loss of Taste/Smell	5 (6.3)	2 (5.0)	3 (7.5)	1
Muscle/Joint pain	31 (38.8)	15 (37.5)	16 (40.0)	0.818
Chest Pain	15 (18.8)	8 (20.0)	7 (17.5)	0.775
Headache	13 (16.3)	8 (20.0)	5 (12.5)	0.363
Weakness	14 (17.5)	5 (12.5)	9 (22.5)	0.239
Gastrointestinal Side Effect	25 (31.3)	9 (22.5)	16 (40.0)	0.091
Vital signs at baseline, mean (SD)				
Temperature (Min)	36.4 (0.2)	36.32 (0.23)	36.3 (0.41)	0.148
Temperature (Max)	37.2 (0.6)	37.1 (0.7)	37.2 (0.6)	0.971
Systolic Blood Pressure (Min)	111.1 (13.0)	119.2 (19.2)	107.3 (16.9)	0.585
Systolic Blood Pressure (Max)	133.9 (15.5)	162.0 (29.6)	140.2 (15.4)	0.416
Diastolic Blood Pressure (Min)	63.5 (8.9)	73.2 (13.4)	56.5 (7.3)	0.7
Diastolic Blood Pressure (Max)	82.3 (10.4)	101.8 (16.2)	84.7 (9.5)	0.717
Heart Rate (Min)	67.2 (10.4)	62.6 (7.4)	67.5 (15.3)	0.601

Heart Rate (Max)	88.4 (13.4)	95.4 (12.3)	99.5 (33.9)	0.185
Respiratory Rate (Min)	18.1 (2.3)	14.2 (5.4)	18.5 (1.6)	0.702
Respiratory Rate (Max)	22.9 (4.4)	29.2 (5.5)	32.0 (4.9)	0.781
O_2 Saturation % (Min)	93.4 (2.4)	93.0 (3.1)	92.3 (2.7)	0.782
WHO Score at baseline, median (IQR)	5 (0)	5.0 (0)	5.0 (0)	0.859
5 (%)	69 (86.3)	35 (87.5)	34 (85.0)	NA
6 (%)	8 (10.0)	2 (5.0)	6 (15.0)	NA
7 (%)	3 (3.7)	3 (7.5)	0	NA
Bilateral abnormality at baseline x-ray	74 (92.5)	38 (95.0)	36 (90.0)	0.675
Concomitant Medications				
Remdesivir (n, %)	67 (83.8)	36 (90.0)	31 (77.5)	0.13
Favipiravir (n, %)	42 (52.5)	18 (45.0)	24 (60.0)	0.179
Corticosteroids (n, %)	80 (100)	40 (100)	40 (100)	NA
Convalescent plasma (n, %)	54 (67.5)	24 (60.0)	30 (75.0)	0.152
Azithromycin (n, %)	63 (78.8)	33 (82.5)	30 (75.0)	0.412
Ceftriaxone (n, %)	63 (78.8)	29 (72.5)	34 (85.0)	0.172
Anticoagulant use (n, %)	79 (98.8)	39 (97.5)	40 (100)	1

268

The change in vital signs and laboratory data over time (i.e. from baseline to day 14) were illustrated in figures 1-36 in the supplementary materials. No significant difference over time in the two treatment groups was noted except for the lymphocyte count (marginal; p=0.046). Figure.2 demonstrates a significant change in WHO score (p=0.000) over 14 days.





282 Outcomes:

- Table 2 below illustrates the results of the primary and secondary outcomes for the two treatment groups.
- 284 The percentage of patients with treatment success at day 14 was not significantly different between the
- two groups (p=0.712). None of the secondary outcomes were found to be statistically significant.

286

Table 2: Results of the primary and secondary outcomes					
Outcome	Overall	Anakinra	Standard of care	P-value	
	(n=80)	(n=40)	(n=40)		
Primary outcome:					
Percentage of patients with treatment success at	72 (90.0)	35 (87.5)	37 (92.5)	0.712	
day 14, n (%)					
Secondary outcomes:					
Duration of mechanical ventilation in ventilated	6.50 (2.0)	6.50 (2.0)	NA	NA	
patients up to day 14, median days (IQR)					
Change in WHO score from baseline to day 7,	1 (0 - 1)	1 (1)	1 (1)	0.211	
median (IQR)					
Change in viral burden (CT value) from baseline to	13.1 (7.8 - 23.2)	6.1 (14.9)	9.8 (7.7)	0.09	
day 7, median (IQR)					
Change in viral burden (CT value) from baseline to	17.6 (8.5 - 23.9)	15.8 (16.0)	17.6 (17.0)	0.923	
day 10-14, median (IQR)					
Time to ICU admission in non-ICU patients up to 28	6.0 (4.0 – 15.0)	7.5 (13.0)	6.0 (15.3)	1.00	
days, median time (IQR)					
Length of hospital Stay, median days (IQR)	10.0 (8.0 - 13.0)	10.0 (4)	10.0 (4)	0.064	
All-cause mortality, n (%)	1 (1.25)	0 (0)	1 (2.5)	1.000	

287

The association between baseline characteristics and the primary outcome was not statistically significant
between the two groups (refer to supplementary materials).

290

291 Safety Outcomes

Two DSMB meetings were conducted as planned, in which the study's progress, execution, results, and adverse event reports were reviewed by the committee members. At each meeting, the decision was made to proceed with the study accrual. A total of 377 adverse events were identified in the study. All patients had at least one adverse event, with an average of 4.7 events per patient. The majority of adverse

296 events (61%) were mild in severity and did not cause harm to patients. Furthermore, 78% of the reported 297 adverse events were judged by a blinded assessor to be not related to the study, 21% "possibly related", 298 and 1% "definitely related" to the study treatment. The most common adverse events were hypertension 299 (65%), followed by increase in alanine aminotransferase, hypoalbuminemia, and sinus bradycardia (43.8% 300 for the three events). Only increased aspartate aminotransferase level was found to be significantly higher in the anakinra group compared to the SOC group (35% vs. 15%), respectively, (p=0.039). Four serious 301 302 adverse events were reported in the study, two in the anakinra group and two in the SOC group. To 303 elaborate, one patient in the SOC died 23 days after randomization due to worsening of his pre-existing 304 medical condition, while the second patient had a prolonged hospital stay due to diarrhea, in which both 305 were judged to be unrelated to study interventions. In the anakinra group, both patients were re-admitted 306 to the hospital for 3-6 days after two weeks of randomization due to suspected respiratory tract 307 infections, which were judged to be possibly related to the study interventions. Table 3 summarizes the 308 common adverse events reported in the study.

Table 3: Reported Adverse Events for Study Groups					
Adverse events, n (%)	Overall	Anakinra	Standard of care	P-value	
	(n=80)	(n=40)	(n=40)		
Incidence of at least one AE	80 (100)	40 (50)	40 (50)	NA	
Average number of AE per patient	4.7	4.7	4.72	0.034	
Serious AE	4 (5)	2 (2.5)	2 (2.5)	NA	
Number of Adverse events	377/377 (100)	201/377 (53)	176/377 (47)	NA	
Severe AE (grade 4-5)	1/377 (0)	0/377 (0)	1/377 (0)	NA	
Mild-Moderate AE (grade 1-3)	376/ 377 (100)	201/377 (53)	175/377 (46)	0.034	
Relatedness to study intervention					
Not related	294/377 (78)	154/377 (41)	140/377 (37)	0.863	
Possibility related	79/377 (21)	44/377 (12)	35/377 (9)	0.534	
Probably related	2/377 (1)	1/377 (0)	1/377 (0)	NA	
Definitely related	2/377 (1)	2/377 (1)	0/377 (0)	NA	
Common AE (incidence > 5%)					
Hypertension	52 (65.0)	27 (67.5)	25 (62.5)	0.639	
Alanine aminotransferase increased	35 (43.8)	19 (47.5)	16 (40.0)	0.499	
Hypoalbuminemia	35 (43.8)	18 (45.0)	17 (42.5)	0.822	
Sinus Bradycardia	35 (43.8)	16 (40.0)	19 (47.5)	0.499	
Hypotension	32 (40.0)	19 (47.5)	13 (32.5)	0.171	
Anemia	21 (26.3)	8 (20.0)	13 (32.5)	0.204	
Aspartate aminotransferase increased	20 (25.0)	14 (35.0)	6 (15.0)	0.039	
Hyponatremia	20 (25.0)	11 (27.5)	9 (22.5)	0.606	

Page 14 of 22

Hyperglycemia	17 (21.3)	9 (22.5)	8 (20.0)	1
Lymphocyte count decreased	15 (18.8)	8 (20.0)	7 (17.5)	0.775
ECG QT corrected interval prolonged	9 (11.3)	5 (12.5)	4 (10.0)	1
Alkaline phosphatase increased	8 (10.0)	5 (12.5)	3 (7.5)	0.712
Diarrhea	8 (10.0)	3 (7.5)	5 (12.5)	0.712
Hyperkalemia	7 (8.8)	5 (12.5)	2 (5.0)	0.432
Hypokalemia	7 (8.8)	3 (7.5)	4 (10.0)	1
Sinus tachycardia	6 (7.5)	4 (10.0)	2 (5.0)	0.675
Lymphocyte count increased	4 (5.2)	2 (5.0)	2 (5.0)	1.000
Creatinine increased	4 (5.2)	2 (5.0)	2 (5.0)	1.000

309

310 **Discussion:**

311 This open-label randomized multicenter clinical trial conducted in Qatar between October 2020 and April 2021, found that anakinra administered SC was not more efficacious than the SOC therapy in patients 312 313 with COVID-19 pneumonia in terms of achieving higher rates of treatment success; defined as a WHO 314 clinical progression score of 3 or less. The use of anakinra was also not associated with a significant change 315 in the WHO clinical progression score or reducing viral burden at 14 days when compared to usual care. 316 The length of stay and the time to ICU admission for non-ICU patients did not differ between the two 317 groups. The overall mortality rate was low in this trial (1.25%) as only one death was reported in the SOC 318 group.

319 The main findings in our trial are consistent with that of the randomized clinical trial by the CORIMUNO 320 collaborative group from France ^[15], which is the only published RCT investigating the use of anakinra to 321 this date. The CORIMUNO-ANA-1 trial was an open-label, multicenter, randomized controlled trial of 322 anakinra administered intravenously (IV) for 5 days compared to usual care to assess its survival benefits 323 and the need for mechanical ventilation at day 4. Similar to our population, the CORIMUNO trial included 324 patients with a WHO clinical progression score of \geq 5. The two primary outcomes were not significant, 325 and the need for mechanical or non-invasive ventilation at day 14 was also not different in both groups. 326 Overall mortality at days 28 and 90 did not differ between the groups, and as a result the trial was prematurely stopped for futility. 327

Anakinra is FDA approved for use in rheumatoid arthritis, neonatal-onset multisystem inflammatory disease, and deficiency of IL-1 receptor antagonist. It has also been utilized in various other clinical situations, most notably its off-label use in the treatment of hemophagocytic lympho-histiocytosis and cytokine storms ^[16,17]. The hyperinflammation seen in patients with COVID-19 pneumonia is associated Page **15** of **22**

with severe disease presentation and is often identifiable by elevation of common inflammatory markers such CRP, IL-6, and procalcitonin, as well as other cytokines ^[18]. In addition, earlier studies suggested a significant role of raised cytokines, including IL-1, in severe COVID-19 pneumonia, which hypnotized a potential role of IL-1 inhibitors in patients with COVID-19 pneumonia ^[6,17].

Several case series and observational studies suggested the potential clinical improvement and mortality benefit of anakinra use in COVID-19 pneumonia ^[19-21]. A recent meta-analysis of 15 observational and interventional studies with a total of 3530 patients suggested that there is an overall mortality benefit with the use of anakinra when compared to usual care ^[22]. Evidence also suggested that anakinra can prevent the progression to severe disease and reduce the need for mechanical ventilation. However, these studies were limited by the lack of randomization and the potential for selection and confounding bias, as well as the significant heterogeneity observed in the meta-analysis outcomes.

343 Unfortunately, the mortality benefit observed in the previous observational studies was not observed in 344 our trial or the CORIMUNO-ANA-1 trial ^[15]. Despite including patients with severe COVID-19 pneumonia, 345 this trial reported only one patient death (1.25%) in the SOC group. On the other hand, the CORIMUNO-346 ANA-1 trial reported an overall mortality rate of 28 % in each group. The advanced SOC may partly explain 347 the low mortality rate in this trial compared to the CORIMUNO-ANA-1 trial. To explain, in the three sites, 348 SOC for all patients included administration of dexamethasone and remdesivir as per the national 349 treatment guidelines. However, none of the CORIMUNO-ANA-1 trial patients received antivirals like 350 remdesivir or favipravir, and dexamethasone was not established as part of routine care for moderate to 351 severe pneumonia by then. Dexamethasone in the RECOVERY trial showed mortality benefit and, eventually, became standard of care globally for treating severe COVID-19^[23]. The Infectious Disease 352 353 Society of America treatment guidelines recommend using remdesivir in patients requiring supplemental 354 oxygen and in patients with moderate to severe COVID-19 pneumonia, given its proven clinical benefits 355 in this population ^[24].

There is an increased interest to prevent severe respiratory failure and the need for intubation and mechanical ventilation in patients presenting with COVID-19 pneumonia. Small case series from the United States initially showed that IV administration of anakinra prevented the development of severe acute hypoxic respiratory failure^[19]. Another meta-analysis of seven studies (including the CORIMUNO ANA-1 trial), with a total of 740 patients receiving anakinra, showed that anakinra reduced the need for invasive mechanical ventilation^[22]. The considerable heterogeneity in these studies as well as the predominantly retrospective and observational nature of those studies, warranted the confirmation of

these findings in a randomized clinical trial. However, no significant benefit was observed by either this
 trial or the CORIMUNO- ANA-1 trial with regards to the rates of invasive mechanical ventilation.

365 The preferred core outcomes for clinical studies as defined by the WHO working group^[13] were used in 366 this trial. Cycling Threshold (CT) is used as a marker of viral load, as it is inversely related to the viral load 367 and provides an indirect method of quantifying the copy number of viral RNA^[25]. Anakinra did not affect 368 the viral burden when compared to the SOC group in this study. Furthermore, the WHO clinical 369 progression scale is a 10-point ordinal scale from 0 (no disease) to 10 (dead). It was chosen as an objective 370 outcome measure to reduce the variability and heterogeneity seen in the previous studies and allow 371 comparisons with future studies. No significant changes were reported in the baseline of the WHO clinical 372 progression score or the seven-days score between the two groups.

373 Overall, a higher prevalence of adverse events was reported in this trial as compared to other studies, 374 with every patient experiencing at least one adverse event. The most commonly reported adverse events 375 were hypertension, raised liver transaminases, and hypoalbuminemia. Only AST elevation was 376 significantly higher in the anakinra group. Although AST elevation is one of the possible adverse effects of 377 anakinra, the possibility that the reported increase in this trial might be due to the multiple concomitant 378 medications taken by the patients cannot be denied. Overall, the incidence of severe adverse events did 379 not exceed 5%. The high prevalence of adverse events in our trial may partially be attributed to the robust 380 data collection and the additional concomitant use of antivirals as part of SOC therapy compared to SOC 381 in other studies. Convalescent plasma has also been part of Qatar's national guidelines, and patients 382 received it as per protocol. The decision was made by the treating physician in line with the criteria set 383 for use as per the national CDC guidelines (refer to supplementary materials).

384 There is increased awareness of the concept of the possible narrow therapeutic window to treat cytokine 385 storms with cytokine inhibitors as well as the right time to initiate IL-1 inhibitors^[26]. There is a need to 386 define if certain inflammatory markers or other biomarkers can guide the right timing for the use of 387 anakinra. Soluble urokinase plasminogen activator receptor (SuPAR), a molecular measurable marker, is 388 associated with increased risk of severe respiratory failure and has also been found to be elevated in 389 patients with COVID-19^[27,28]. An open-label non-randomized interventional trial (SAVE) was done to 390 assess the use of anakinra to prevent progression to severe COVID-19 disease ^[29]. The trial included 130 391 patients in the anakinra group and 130 propensity-matched SOC comparator cohort. Patients who had a 392 level higher than 6 microg/l were deemed at risk of developing severe respiratory failure and, thus, were 393 treated with anakinra. Anakinra successfully prevented the need for mechanical ventilation and

394 demonstrated mortality benefits. SAVE trial, although inadequate randomization, provided additional 395 insights that patients with biomarker-guided therapy may be better candidates to receive the specific 396 interleukin inhibitors. This is being investigated by the ongoing placebo-controlled randomized (SAVE-397 MORE) phase III trial assessing the effects of biomarker-guided use of anakinra in patients. (www.clinicaltrials.gov, NCT04680949)^[27]. Similarly, another non-randomized study, where ferritin was 398 399 used as a biomarker to guide therapy, showed significantly improved clinical outcomes, including reduced 400 mortality rates and progression to severe COVID-19 by early administration of therapy either with 401 anakinra alone or in combination with steroids^[30].

The route of administration of anakinra used in our trial was subcutaneous, while it was intravenously administered in the CORIMUNO-ANA-1 trial. Both did not show any significant benefits in their defined outcomes. Whether higher doses or extended duration of anakinra could have benefited the COVID-19 patients is unknown and may warrant further investigation.

This trial has some limitations. First, a placebo was not used in this trial due to the nature of the pandemic and the urgency to answer the clinical question. In addition, there is a potential for bias due to the openlabel nature of the trial. However, this was minimized by choosing objective outcomes and blinding the outcome assessors. Finally, the overall sample size was small, especially for patients with severe disease or mechanical ventilation; hence, subgroups analysis in this population was not feasible.

411 On the other hand, this trial has several strengths. This trial is one of the few randomized trials conducted 412 on COVID-19 patients after establishing a better SOC (steroids, remdesivir). Moreover, it was a multicenter 413 trial involving multiple ethnic groups, contributing to the study results' higher generalizability. The WHO's 414 recommended outcomes for clinical studies were used; those included the WHO clinical progression score, viral burden as measured by the cyclic threshold, and the overall mortality, which facilitate the 415 416 comparison of this trial's results to other similar trials. Furthermore, this trial was conducted in Qatar 417 where well-established national guidelines for COVID-19 treatment exist. Finally, no significant loss of 418 follow-up rate was reported in this study.

419 **Conclusion:**

In patients with severe COVID-19 pneumonia requiring oxygen therapy, the addition of anakinra to the
SOC treatment was not associated with significant improvement in the WHO clinical progression scale.
Therefore, there is a need for determining the subgroups of COVID-19 patients who will benefit the most
by the timely administration of anakinra.

424 Author Contributions

- 425 Conceptualization and Methodology: Eman Elmekaty. Data Validation: Mohamed Aboukamar, Waqar
- 426 *Munir, Rim Alibrahim, Eman Elmekaty. Formal analysis and Visualization: Mohamed Izham.* Investigations:
- 427 Wagar Munir, Ahmed Al Bishawi, Arun Nair, Aya Maklad, Rawan Abouelhassan, Fatima Igbal, Mohammed
- 428 AbuKhattab, Rim Alibrahim, Mohamed Aboukamar, Alaaeldin Abdelmajid. Resources: Hussam Al Soub,
- 429 Mohammed AbuKhattab, Muna Al Maslamani. Data curation: Aya Maklad, Rawan Abouelhassan, Eman
- 430 Elmekaty. Writing original draft: Ahmed Al Bishawi, Arun Nair, Mohamed Izham, Fatima Iqbal. Writing
- 431 review & editing: Aya Maklad, Rawan Abouelhassan, Mohamed AbuKhattab, Eman Elmekaty, Hussam
- 432 Al Soub, Alaaeldin Abdelmajid. Supervision: Hussam Al Soub, Muna Al Maslamani.

433 Data sharing

- 434 Deidentified participants data (in spreadsheet form, with included data definitions) will be made available
- 435 for sharing after publication on reasonable requests made to the corresponding author. Data can be
- 436 shared through secure online platforms after being approved by the principal investigator.

437 **Declaration of interests**

438 All authors declare that they have no conflict of interest.

439 Acknowledgments:

- 440 We would like to thank all physician assistants working in Hamad Medical Corporation COVID-19
- 441 facilities for their outstanding support and dedication.

442 References

- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2
 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J
 Antimicrob Agents. 2020 Feb 17:105924. doi: 10.1016/j.ijantimicag.2020.105924. [Epub ahead of
 print]
- 447 2. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization, 2020.
 448 https://Covid19.who.int/. [Accessed 29 March 2020.]
- 449 3. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China.
 450 MedRxiv 2020: 2020.02.06.20020974.
- 4. WHO Director-General's opening remarks at the media briefing on COVID-19 3 March 2020 World Health Organization, March 3, 2020

- 453 5. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate
 454 coronavirus disease 2019. J Clin Invest 2020;130:2620-9. doi:10.1172/JCI137244
- 455 6. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and 456 immunosuppression. Lancet 2020; 395: 1033–34.
- McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in
 COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun
 Rev 2020; published online April 3. DOI:10.1016/j.autrev.2020.102537.
- 8. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1
 receptor blockade is associated with reduced mortality in sepsis patients with features of
 macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275–
 81.
- 9. Opal SM, Fisher Jr CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1
 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebocontrolled, multicenter trial. Crit Care Med. 1997;25:1115–24.
- 467 10. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet
 468 Rheumatol. 2020;9913(20):1-8. doi:10.1016/s2665-9913(20)30164-8
- 11. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in
 patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a
 retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331. doi:10.1016/S26659913(20)30127-2
- 473 12. Langer-Gould A, Smith JB, Gonzales EG, et al. Early identification of COVID-19 cytokine storm and
 474 treatment with anakinra or tocilizumab. Int J Infect Dis. 2020;99:291-297.
 475 doi:10.1016/j.ijid.2020.07.08
- 476 13. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome
 477 measure set for COVID-19 clinical research. The Lancet Infectious Diseases. 2020;20(8):e192-e7.
- 478 14. National Cancer Institute. Common Terminology Criteria for Adverse Events Version 5.0.
 479 2017.Available from: <u>https://ctep.cancer.gov/protocoldevelopment/electronic applications</u>
 480 /docs/ctcae v5 quick reference 5x7.pdf
- 481 15. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate
 482 pneumonia (CORIMUNO-ANA-1): a randomized controlled trial. Lancet Respir Med. 2021
 483 Mar;9(3):295–304.

- Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra,
 an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic
 lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in
 critically ill children*. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit
 Care Soc. 2014 Jun;15(5):401–8.
- 489 17. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of
 490 intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation
 491 syndrome. Lancet Rheumatol. 2020 Jun;2(6):e358–67.
- 492 18. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the
 493 severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020 Jul;96:467–74.
- 494 19. Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent
 495 Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol Hoboken Nj. 2020
 496 Jun 30;10.1002/art.41422.
- 497 20. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory
 498 cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis.
 499 2020 Oct;79(10):1381–2.
- 500 21. Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al.
 501 Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic
 502 Lymphohistiocytosis. Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1.
- 503 22. The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A
 504 Systematic Review and Meta-Analysis [Internet]. [cited 2021 Aug 14]. Available from:
 505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258297/
- 506 23. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 –
 507 Preliminary Report. N Engl J Med. 2020 Jul 17;NEJMoa2021436.
- 508 24. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious Diseases
 509 Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin
 510 Infect Dis Off Publ Infect Dis Soc Am. 2020 Apr 27;ciaa478.
- 25. Rao SN, Manissero D, Steele VR, Pareja J. A Narrative Systematic Review of the Clinical Utility of
 Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. 2020 Sep;9(3):573–86.
- 513 26. Cavalli G, Dagna L. The right place for IL-1 inhibition in COVID-19. Lancet Respir Med. 2021
 514 Mar;9(3):223–4.

- 515 27. Hellenic Institute for the Study of Sepsis. suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-516 517 blind, Randomized, Phase III Confirmatory Trial [Internet]. clinicaltrials.gov; 2021 Apr [cited 2021 12]. NCT04680949. 518 Aug Report Available from: No.: 519 https://clinicaltrials.gov/ct2/show/NCT04680949 520 28. Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble
- urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory
 failure in patients with COVID-19 pneumonia. Crit Care. 2020 Apr 30;24:187.
- 523 29. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open
 524 label trial of anakinra to prevent respiratory failure in COVID-19. eLife. 10:e66125.
- 30. Dalekos GN, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G, et al. Lessons from
 pathophysiology: Use of individualized combination treatments with immune interventional
 agents to tackle severe respiratory failure in patients with COVID-19. Eur J Intern Med. 2021
 Jun;88:52–62.

529